FCGR1A antibody (PE)

Catalog No. ABIN1112217

Product Details anti-FCGR1A Antibody (PE)

Target: FCGR1A (Fc Fragment of IgG, High Affinity Ia, Receptor (CD64) (FCGR1A))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This FCGR1A antibody is conjugated to PE

Application: Flow Cytometry (FACS), Immunofluorescence (IF)

Characteristics: Monoclonal Mouse Anti-Human CD64 for identification of CD64 a high affinity receptor for human IgG (FcgammaRI) expressed on monocytes, macrophages, dendritic cells, granulocytes activated with interferon-gamma and early myeloid lineage cells.

Immunogen: Rheumatoid synovial fluid cells and fibronectin purified human monocytes

Clone: 10-1

Isotype: IgG1

Application Details

Application Notes: It is recommended for use in flow cytometry. This reagent is effective for direct immunofluorescence staining of human tissue for flow cytometric analysis using 20 µl/10^6 cells.

Comment:

R-Phycoerythrin. Abs/Em. Max.: 565/575 nm. Anti-CD64 10, 1 was included in the 6th International Workshop on Human Leucocyte Differentiation Antigens (Code MA36).

Sample Collection: 1. Transfer 100 µl of anticoagulated (EDTA) blood to a 12 x 75 mm polystyrene test tube (10^6 cells). 2. Add 20 µl of CD64 PE and mix gently with a vortex mixer. The 20 µl is a guideline only, the volume should be determined by the individual laboratory. 3. optimal The recommended negative control is a non-reactive PE-conjugated antibody of the same isotype. 4. Incubate in the dark at room temperature at 4°C for 30 minutes or at room temperature (20-25 °C) for 15 minutes. 5. Add 1,5 ml of Lysing Solution to each sample and mix gently with a vortex mixer. Incubate for 10 minutes at room temperature in the dark. 6. Centrifuge at 1000 x g for 5 minutes. Gently aspirate the supernatant and discard it leaving approximately 50 µl of fluid. 7. Add 2 ml 0.01 mol/l PBS (It betters that it containing 2% bovine serum albumin) and resuspend the cells by using a vortex mixer. 8. Centrifuge at 1000 x g for 5 minutes. Gently aspirate the supernatant and discard it leaving approximately 50 µl of fluid. 9. Resuspend pellet in an appropriate fluid for flow cytometry, e.g. 0.3 ml PBS. The PBS should contain 1% paraformaldehyde (fixative) if samples are not analysed the same day. 10. Analyse on a flow cytometer or store at 2-8 °C in the dark until analysis. Samples can be run up to 24 hours after lysis.

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: The conjugate is provided in liquid form in buffer containing Antibody Stabilizer solution PBS 20 mM and 0,09% Sodium azide, pH 7.2.

Preservative: Sodium azide

Precaution of Use: 1. The device is not intended for clinical use including diagnosis, prognosis, and monitoring of a disease state, and it must not be used in conjunction with patient records or treatment. 2. This product contains Sodium azide (NaN3), a chemical highly toxic in pure form. At product concentrations, though not classified as hazardous, Sodium azide may react with lead and copper plumbing to form highly explosive build-ups of metal azides. Upon disposal, flush with large volumes of water to prevent metal azide build-up in plumbing. 3. As with any product derived from biological sources, proper handling procedures should be used.

Storage: 4 °C

Target Details for FCGR1A

Target: FCGR1A (Fc Fragment of IgG, High Affinity Ia, Receptor (CD64) (FCGR1A))

Alternative Name: CD64 (FCGR1A Products)

Synonyms: CD64 antibody, CD64A antibody, FCRI antibody, IGFR1 antibody, FcgammaRI antibody, Fcgr1 antibody, Fcgr1b antibody, AI323638 antibody, AV092959 antibody, IGGHAFC antibody, FCGR1A antibody, Fc fragment of IgG receptor Ia antibody, Fc receptor, IgG, high affinity I antibody, FCGR1A antibody, Fcgr1a antibody, Fcgr1 antibody

Background: Monocytes, macrophages, dendritic cells, granulocytes activated with interferon- gamma and early myeloid lineage cells express CD64, while mature granulocytes and lymphocytes are negative. CD64 functions in both innate and adaptive immune responses and mediates endocytosis, phagocytosis, antibody-dependent cellular toxicity, cytokine release and superoxide generation

Pathways: Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process